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http://www.trialsjournal.com/content/15/1/371STUDY PROTOCOL Open AccessThe REFLO-STEMI trial comparing intracoronary
adenosine, sodium nitroprusside and standard
therapy for the attenuation of infarct size and
microvascular obstruction during primary
percutaneous coronary intervention: study
protocol for a randomised controlled trial
Sheraz A Nazir1, Jamal N Khan1, Islam Z Mahmoud2, John P Greenwood3, Daniel J Blackman3, Vijay Kunadian4,
Martin Been5, Keith R Abrams6, Robert Wilcox7, AA Jennifer Adgey8, Gerry P McCann1 and Anthony H Gershlick1*Abstract
Background: Microvascular obstruction (MVO) secondary to ischaemic-reperfusion injury is an important but
underappreciated determinant of short- and longer-term outcome following percutaneous coronary intervention
(PCI) treatment of ST-elevation myocardial infarction (STEMI). Several small studies have demonstrated a reduction
in the degree of MVO utilising a variety of vasoactive agents, with adenosine and sodium nitroprusside (SNP) being
most evaluated. However, the evidence base remains weak as the trials have had variable endpoints, differing drug
doses and delivery. As such, the results regarding benefit are conflicting.
Methods: The REperfusion Facilitated by LOcal adjunctive therapy in STEMI (REFLO-STEMI) trial is a multicentre,
prospective, randomised, controlled, open label, study with blinded endpoint analysis: Patients presenting within 6
h of onset of STEMI and undergoing planned primary PCI (P-PCI) with TIMI 0/1 flow in the infarct-related artery (IRA)
and no significant bystander coronary artery disease on angiography, are randomised into one of three groups: PCI
with adjunctive pharmacotherapy (intracoronary adenosine or SNP) or control (standard PCI). All receive Bivalirudin
anticoagulation and thrombus aspiration. The primary outcome is infarct size (IS) (determined as a percentage of
total left ventricular mass) measured by cardiac magnetic resonance imaging (CMRI) undertaken at 48 to 72 h post
P-PCI. Secondary outcome measures include MVO (hypoenhancement within infarct core) on CMRI, angiographic
markers of microvascular perfusion and MACE during 1-month follow-up. The study aims to recruit 240 patients
(powered at 80% to detect a 5% absolute reduction in IS).
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Discussion: The REFLO-STEMI study has been designed to address the weaknesses of previous trials, which have
collectively failed to demonstrate whether adjunctive pharmacotherapy with adenosine and/or SNP can reduce
measures of myocardial injury (infarct size and MVO) and improve clinical outcome, despite good basic evidence
that they have the potential to attenuate this process. The REFLO-STEMI study will be the most scientifically robust
trial to date evaluating whether adjunctive therapy (intracoronary adenosine or SNP following thrombus aspiration)
reduces CMRI measured IS and MVO in patients undergoing P-PCI within 6 h of onset of STEMI.
Trial registration: Trial registered 20th November 2012: ClinicalTrials.gov Identifier NCT01747174.
Keywords: Cardiovascular magnetic resonance, Myocardial infarction, Microvascular obstruction, Adenosine,
Nitroprusside, Primary angioplastyBackground
Timely delivered primary percutaneous coronary interven-
tion (P-PCI) has become the favoured reperfusion therapy
for ST-elevation myocardial infarction (STEMI) in the US
and Europe [1]. However, this interventional technique
has not abolished the unpredictable phenomenon of
no-reflow and the underappreciated, but potentially equally
important, syndrome of normal epicardial-microvascular
obstruction (MVO).
MVO describes abnormal tissue perfusion and/or coron-
ary blood flow despite normal patency of the infarct-related
artery (IRA) [2]. This can result in persistent myocardial
injury and necrosis through interacting processes. Distal
microembolisation of thrombus and plaque debris, activa-
tion of the inflammatory cascade, neutrophil plugging,
toxic free-radical generation and capillary obstruction
by intra-luminal (endothelial protrusion by cell swelling
and cellular infiltrate rich in red-blood cells, platelets
and granulocytes) and extra-luminal (compression from
surrounding oedematous myocytes) mechanisms promote
poor perfusion and irreversible injury to potentially viable
myocytes [2-9]. These ultrastructural and functional changes
result in a spectrum of MVO that, as detected by cardiac
magnetic resonance imaging (CMRI), manifests in up to
70% of patients with STEMI treated with P-PCI [10-16].
Although the incidence of MVO varies between studies,
presumably due to a combination of modifiable and non-
modifiable patient-related factors, its presence has been
reported to be associated with major adverse cardiac event
(MACE) rates of up to 30% at 1 month and 60% at 12
months [11].
Manual thrombectomy has been shown to improve
angiographic microvascular flow irrespective of the pres-
ence of visible thrombus [17], and to reduce infarct size
(IS) and preserve microvascular integrity assessed by
CMRI [18], leading to improved left ventricular (LV)
function and tissue perfusion assessed by myocardial
contrast echocardiography (MCE) [19]. However, there
is conflicting evidence as to whether this leads to overall
improved clinical outcomes [20-26] although the large
ongoing TOTAL trial will provide further insight [27].Glycoprotein IIb/IIIa (GPIIbIIIa) inhibitors further reduce
IS and improve markers of microvascular perfusion in
STEMI patients undergoing P-PCI [28-30]. Bivaluridin has
been shown in the ACUITY [31] and HORIZONS-AMI
[32] trials to provide similar efficacy with less bleeding
and even reduced mortality compared with unfractionated
heparin plus GPIIb/IIIa receptor inhibitors in high-risk
patients undergoing PCI. However, residual mortality and
subsequent MACE rates suggest there is room for improve-
ment even in those patients who do not demonstrate slow
or no-reflow angiographically.
Basic understanding of the MVO process has led to
the evolution of several treatment regimens designed to
improve outcomes, and include the use of vasodilators
[33-41], albeit mostly in clinical trials. Of these, sodium
nitroprusside (SNP) [12,42-49] and adenosine [44,50-62]
and their effect on attenuating or preventing MVO have
been the most studied. The randomised controlled trials
of adenosine and SNP in P-PCI are presented in Table 1
(Additional file 1). Adenosine, aside from being a potent
vasodilator [63], may have additional benefits due to its
pleiotropic effects: the anti-inflammatory action of adeno-
sine is well recognised [64,65] and its ability to block
the neutrophil-mediated processes that promote MVO
may explain the reduction of reperfusion injury seen with
intracoronary (IC) adenosine in canine infarct models
[66]. Similarly SNP, a direct nitric oxide (NO) donor
that requires no intracellular metabolism [67], utilises
NO’s multiple vascular functions. These include vaso-
dilatation of arterioles, inhibition of platelet adhesion and
anti-inflammatory activity [68], which effectively reduce
no-reflow in animal reperfusion-injury models [69,70].
SNP and adenosine have, in some trials, demonstrated
favourable improvement in electrocardiographic (ECG)
and angiographic markers of microvascular perfusion, as
well as improvements in short-term MACE [42,44,55,71].
The randomised and placebo-controlled Acute Myocardial
Infarction STudy of ADenosine (AMISTAD)-II trial sought
to determine the benefit of adenosine in 2,118 patients
presenting within 12 h of onset of anterior STEMI treated
with thrombolysis (60%) or P-PCI (40%) [59]. IS and
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
● Aged ≥18 years ● Contraindications to: P-PCI, CMRI, gadolinium-based and/or iodinated contrast
agents, or study medications: Adenosine, SNP, Aspirin, Thienopyridine and Bivalirudin
● Informed ASSENT (verbal consent) prior to angiography
● STEMI ≤6 h of symptom onset, requiring P-PCI ● SBP ≤90 mmHg
● Single-vessel coronary artery disease (non-culprit
disease <70% stenosis at angiography)
● Cardiogenic shock
● Previous Q wave myocardial infarction
● Culprit lesion not identified or located in a bypass graft● TIMI flow 0/1 at angiography
● Stent thrombosis
● QTc <450 ms ● Left main disease
● Known severe asthma
● Known stage 4 or 5 chronic kidney disease (eGFR <30 mL/min/1.73 m2)
● Pregnancy
CMRI, cardiac magnetic resonance imaging; e-GFR, estimated glomerular filtration rate; P-PCI, primary percutaneous coronary intervention; SBP, systolic blood
pressure; TIMI, Thrombolysis in Myocardial Infarction.
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who received a higher (70 μg/kg/min) dose of adeno-
sine and in those reperfused within 3 h of symptom
onset. This trial, although the largest to date, has a
number of limitations in addition to the mixed reperfu-
sion strategy cohort: (1) Adenosine was administered
by intravenous (IV) infusion after the PCI; (2) IS was
measured relatively late after presentation in only 11%
of patients and by technetium-99 m sestamibi single-
photon emission computed tomography (SPECT), which
may underestimate IS compared to CMRI; and (3) no
measure of myocardial salvage was obtained. Overall,
AMISTAD-II appears not to be applicable in the modern
P-PCI era.
The effects of adenosine on the coronary microcircula-
tion during STEMI have only been assessed using CMRI
in one previous study. Desmet et al. [51] assessed whether
intracoronary administration of adenosine, distal to the
occlusion site and immediately before initial balloon
inflation, resulted in increased myocardial salvage and
decreased MVO versus placebo on CMR at 48 to 72 h
post P-PCI in 112 patients. They reported no significant
difference in myocardial salvage between the two groups
(41.3% vs. 47.8%, P = 0.52). MVO extent, angiographic
markers of reperfusion and infarct size at 4 months were
also similar in both groups. Interestingly, the authors
reported a statistically significant benefit in favour of
adenosine in patients with Thrombolysis in Myocardial
Infarction (TIMI) 2-3 flow pre-PCI. This suggested that
establishing flow prior to adenosine delivery was benefi-
cial and perhaps necessary for the drug to have a clinical
effect. As thrombectomy was not performed in this study,
it is possible that adenosine may have been ineffective
due to a combination of its short half-life and failure to
reach the distal vascular bed. In addition, more patients
had anterior MI in the adenosine group (48% vs. 33%).Anterior STEMI is known to be associated with larger
ISs, reduced myocardial salvage and increased LV
remodeling [72]. Moreover, the spontaneous reperfusion
rate was high (28%) in this study, evident as TIMI 2-3 flow
prior to P-PCI. The placebo group had almost twice as
many patients with established TIMI 2-3 flow prior to
PCI, and this is known to be associated with higher
myocardial salvage and reduced IS. Finally, the expression
of MVO indexed to the area at risk rather than IS or total
LV mass has not been described previously in the evidence
base and is unexplained in this study.
Although benefits have been shown for both adenosine
and SNP in smaller trials, the results of such studies have
been largely conflicting and hence, there is currently no
consensus on the value of routine administration of
adjunctive pharmaco-therapeutic agents to prevent or
reduce MVO. In fact, a recent Cochrane review found
that adenosine, when given as an adjunct during P-PCI,
did not reduce all-cause mortality, non-fatal myocardial
infarction or the incidence of angiographic no-reflow
[73]. However, the authors conceded that the evidence
base was limited and highlighted the need for further
research with larger high quality trials. Heterogeneity in
trial design (small numbers, sub-optimal drug dosages,
inadequate anti-platelet therapy and variably chosen
endpoints often lacking imaging confirmation of MVO
and IS) has resulted in contradictory outcome data that
may not be clinically applicable. Consequently there is
divergent clinical practice, even within institutions. Further-
more, the incidence of no-reflow/MVO remains difficult to
predict on coronary angiography alone. It could be argued
that, given the strong relationship of MVO to prognosis,
prophylactic prevention of MVO should be considered in
all patients presenting with STEMI, irrespective of the
thrombus burden, with delivery of agents theoretically able
to reduce MVO.
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to show a reduction in MVO may be in part related to
factors other than clinical efficacy. The lack of a sensitive
imaging modality to detect MVO and failure to deliver
vasoactive agents close to the microvascular bed may
potentially have reduced their therapeutic impact.
We therefore designed the REperfusion Facilitated by
LOcal adjunctive therapy in STEMI (REFLO-STEMI)
study to evaluate whether adjunctive adenosine or SNP,
administered in two doses (the first optimally delivered
by distal intracoronary (IC) injection following thrombec-
tomy), would be effective in preventing MVO and reducing
IS, as determined with the sensitive measure of CMRI, in
patients undergoing P-PCI for STEMI.
Methods
The REFLO-STEMI trial is a multicentre, randomised,
controlled, open label, clinical trial (see Figure 1) in four
regional cardiac centres in the United Kingdom, conducted
in compliance with the principles of the Helsinki Declar-
ation. Ethical approval for the study (reference 11/H0405/
10) was obtained from the National Research Ethics Service
(UK). All patients presenting within 6 h of symptom onset
of STEMI, who are suitable for reperfusion by P-PCI and
have a baseline corrected QT interval (QTc) <450 ms on
admission ECG (to limit the risk from the possible QT
prolongation effect of the study drugs), are provisionally
eligible to participate in the study. TIMI flow grade 0-1 in
the IRA and no flow-limiting bystander disease (that is, no
stenosis ≥70% in non-infarct-related arteries (N-IRA)) are
pre-requisites to randomisation (see Table 1 for detailed
eligibility criteria). Following verbal consent or assent
[74,75] patients will be randomised 1:1:1 to: adjunctive IC
adenosine, SNP or control (standard P-PCI alone) using a
dedicated 24/7 computerised telephone service (provided
by the ‘Sealed Envelope Company’, UK) with three stratifi-
cations: 1, ‘symptoms to balloon <3 h or ≥3 h’; 2, ‘anterior
infarction’ or not; and 3, recruiting centre.
In all cases, P-PCI will be performed in line with
accepted practice with trans-radial or femoral arterial
access using 6-7 Fr sheaths. Patients will be pre-treated
with dual antiplatelet therapy with aspirin (300 mg loading
dose and 75 mg/day maintenance) and Prasugrel (60 mg
loading dose and 10 mg/day maintenance) [76,77] or
Ticagrelor (loading dose 180 mg and maintenance dose
of 90 mg twice daily) and given for up to 12 months
[78-80]. Bivalirudin will be administered to all patients
(0.75 mg/Kg bolus plus infusion of 1.75 mg/Kg/hr) in the
absence of specific contraindication, with dose reduction
for renal insufficiency, and will be discontinued at the
completion of P-PCI (but could be continued for 4 h if
clinically indicated). For patients randomised to an
intervention arm, following manual thrombectomy
and thorough flushing of the catheter, the first drugdose (adenosine 1 mg or SNP 250 mcg) will be injected as
distally as possible via the thrombus aspiration catheter.
Immediately following stent deployment, providing repeat
measure of QTc is <450 ms and remains <60 ms increase
over baseline value, the second drug dose (adenosine 1 mg
if IRA is the right coronary artery (RCA) otherwise 2 mg
or SNP 250 mcg) will be injected via the guide catheter.
Administering the second drug dose distal to the stent
was considered but the risk associated with crossing
the stent with the thrombectomy catheter was thought
to outweigh the benefit of distal drug delivery. The
ECG will be recorded and retained at each angiography
time point. The degree of ST-segment resolution (STR)
will be determined from 12-lead ECGs acquired pre- and
post-P-PCI and categorised as complete (>70%), partial
(30% to 70%), or no (<30%) STR [16,81]. The maximal
sum of ST-segment elevation, measured 60 ms after the J
point, will be calculated from three contiguous leads in
the infarct territory. Angiographic images will be acquired
at 30 frames per second with long acquisitions (to visual-
ise the venous phase in contrast passage) in orthogonal
views before intervention and after stenting (at the time
of the final/optimal angiographic result) to enable deter-
mination of angiographic markers of MVO offline at a core
laboratory (Newcastle University). TIMI myocardial perfu-
sion grade (TMPG) will be assessed visually as previously
described [82,83] (Additional file 1). Digital quantification
of myocardial perfusion or ‘blush’ will be performed using
‘QuBE’ software [84]; corrected TIMI frame count (cTFC)
will be calculated as the number of cine-frames needed for
dye to reach standardised distal landmarks, to objectively
evaluate coronary blood flow as a continuous variable
[85,86]. A list of angiographic markers of MVO to be
assessed is provided in Table 2.
Following the P-PCI procedure, and when clinically
stable, the patient will be provided with a detailed study
information leaflet and written informed consent will be
obtained from each participant to continue partaking in
the trial. A 20% drop out rate between P-PCI and CMR
has been allowed for. Studies on informed consent in
acute MI patients have suggested that oral information
is far better received, processed and recalled by patients
compared with the written form [89,90]. In the ISIS-4
patient cohort, 95% recalled receiving the oral information,
whereas only 37% recalled receiving the written consent
form [89]. Furthermore, only 18% of 346 patients pro-
spectively studied reported reading the patient information
sheet before providing or refusing consent to participate in
the HERO-2 acute MI trial [90]. Of particular note is that
patients who gave consent were more likely to report good
or partial understanding of the written material than those
who refused consent. This raises the possibility of selection
bias at the time of consent. Consequently, we believe verbal
explanation of a trial may be a more effective and valuable
Figure 1 Study recruitment diagram.
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Table 2 Study outcome measures
Type of outcome measure Outcome measures
CMRI parameters ● IS (% total LV mass): Primary outcome
● Incidence and extent of MVO (% LV mass)
● Myocardial salvage index (MSI)
● Intra-myocardial haemorrhage (IMH)
● LV ejection fraction (LVEF) and volumes
Angiographic markers of MVO ● TIMI flow grade [87]
● Corrected TIMI frame count (cTFC) [85,86]
● TIMI myocardial perfusion grade (TMPG) [82,83,88]
● Computer-assisted myocardial blush quantification using the software ‘Quantitative Blush Evaluator’ (QuBE) [84]
● Incidence pre- and post-procedure of angiographic true ‘no-reflow’
● Incidence of angiographic slow/no-reflow after P-PCI
ECG ● Degree of ST segment resolution on ECG [16,81]
Echocardiography ● LV function at baseline and 3 months
Sub-analyses ● Comparing CMRI markers with other myocardial perfusion markers (angiographic, ECG and cardiac enzymes)
● Overall MACE and its components at 1 month: death, need for TLR, recurrent MI, severe heart failure and CVE
CMRI, cardiac magnetic resonance imaging; CVE, cerebrovascular event; ECG, electrocardiogram; e-GFR, estimated glomerular filtration rate; LV, left ventricular;
LVEF, MACE, major adverse cardiac events; MI, myocardial infarction; MVO, microvascular obstruction; P-PCI, primary percutaneous coronary intervention;
SBP, systolic blood pressure; TIMI, Thrombolysis in Myocardial Infarction; TLR, target lesion revascularisation.
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emergent situation of STEMI, where treatment must be
provided without undue delay. This approach has been
successfully used in two recent STEMI trials [74,75].
Blood samples will be drawn at baseline and at 4, 12
and 24 h after P-PCI for cardiac enzymes (CK-MB and
Troponin) estimation and at pre-discharge for NT-
proBNP. ECG recording will be undertaken at 90 min,
24 h and pre-discharge. All patients will be commenced
on a beta-blocker, angiotensin converting enzyme (ACE)
inhibitor and high-dose statin in addition to dual anti-
platelet therapy, unless contra-indicated, according to
international guidelines.
Patients will undergo CMRI at 48 to 72 h after presen-
tation with STEMI on a 3.0 T scanner with retrospective
electrocardiographic gating and dedicated cardiac receiver
coils at each of the four participating centres (see Figure 2)
to provide the primary endpoint [91,92]. Prior to contrast
administration, T2-weighted short-tau inversion recovery
(T2w-STIR) imaging with coil SI correction will be
performed in long-axis (LAX) views and contiguous
short-axis (SAX) slices covering the entire LV to assess
for oedema (area at risk, (AAR)). Three SAX (base, mid
and apical) tagged images will be acquired using a pro-
spectively gated spatial modulation of magnetization
(SPAMM) gradient-echo sequence. Early gadolinium
enhancement (EGE) imaging will be acquired 1 to 3
min after 0.15 mmol/kg gadolinium-DTPA (Magnevist,
Bayer, Germany) administration using a single-shot
inversion-recovery gradient-echo sequence. Functional
assessment of LV ejection fraction (LVEF), volumes andmass will be according to current standards with the
use of a steady state free precession (SSFP) cine pulse
sequence covering the whole LV with 8 to 12 contiguous
short axis (SAX) slices. Late gadolinium enhancement
(LGE) imaging [93] will then be performed in LAX (2-,
3- and 4-chamber) views and contiguous SAX slices
covering the whole LV. LGE images will be acquired 10
to 15 min post contrast using a segmented inversion-
recovery gradient-echo sequence. The inversion time will
be progressively adjusted to null unaffected myocardium.
Study outcome measures are listed in Table 3.
CMRI analysis, blinded to patient details, will be under-
taken in a central core lab (University of Leicester) using
cmr42 (Circle Cardiovascular Imaging, Calgary, Canada).
Anonymised CMR images will be graded for image quality
using a 4 point scale before analysis: 4 = excellent; 3 =
good; 2 =moderate; and 1 = non-analysable. Endocardial
and epicardial borders will be manually contoured on
contiguous SAX LV slices, excluding papillary muscles,
trabeculae and blood-pool artefact for LV volumetric,
AAR and IS analyses. Infarct will be identified as enhance-
ment on LGE images and quantified using the Full-Width
Half-Maximum (FWHM) technique [97]. MVO will be
defined (and quantified) as hypoenhancement within
infarcted myocardium, as determined from LGE images,
and will be included in the total IS. Myocardial oedema
will be quantified using semi-automatic thresholding
defining AAR as enhancement within myocardium of
signal intensity >2 standard deviations (SD) above that of
a region of interest (ROI) contoured in remote myo-
cardium. Hypoenhanced areas within the AAR will be
Figure 2 CMRI protocol.
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cardial salvage index (MSI) will be calculated as: 100*
((AAR-IS)/AAR). IS, MVO, AAR and IMH will be
expressed as a percentage of LV end-diastolic mass (%
LVM) and LV volumes will be indexed to body-surface
area. Intra- and inter-observer variability will be reported
for the primary outcome measure.
All patients will be followed up for at least 1 month
following randomisation and throughout the course of
the study until the last patient recruited to the trial has
completed 1-month follow-up. Median follow-up will be
reported. Patients will also be flagged with the Office for
National Statistics to ensure mortality data are captured.
It is anticipated that most adverse events will be expected
as recognised complications of STEMI or the revasculari-
sation procedure. Such events will be recorded for the
evaluation of outcome measures and for safety monitor-
ing. Definitions of important adverse events are provided
in Table 3. Investigators will be required to notify the
coordinating centre (University Hospitals of Leicester,UK) within 24 h if any of the following adverse events
occur: death; a serious deterioration in a patient’s health
that results in life-threatening injury or illness; an event
resulting in permanent impairment of a body structure
or function; an event resulting in medical or surgical
intervention to prevent permanent impairment to body
structure or function; an event prolonging inpatient hospi-
talisation. On receipt of notification of any trial adverse
or clinical event, the co-coordinating centre will request
additional details specific to the nature of the event and
carefully monitor these episodes overall. A clinical events
committee has been established to review and adjudicate
key trial adverse events, blinded to patient details and
treatment allocation, using original source documents.
Statistical methods
Demographics will be presented and values of IS and
MVO will be summarised, both overall and by treatment
group. The distribution of IS will be investigated and the
data will be transformed if found to be non-normally
Table 3 Definitions of adverse events
Adverse event Definition
Cardiogenic shock Systolic blood pressure <90 mmHg for at least 30 min (or the need for supportive measures to maintain a
systolic blood pressure of >90 mmHg) in the presence of a heart rate of >60 beat/min in association with
signs of end-organ hypoperfusion (cold extremities, low urinary output <30 mL/h and/or mental confusion)
Myocardial infarction (MI) MI will be defined differently in specific clinical situations in this trial. The European Society of Cardiology (ESC)
and American College of Cardiology (ACC) criteria for acute, evolving or recent MI will apply
Re-infarction Further chest pain during the index admission lasting >20 min accompanied by new electrocardiographic changes
(new Q waves >0.04 s or ST-segment elevation >0.1 mV in two leads for >30 min), further enzyme rise or both
Recurrent MI A ≥20% rise in the value of the biomarker measured serially 6 to 12 h apart, provided the absolute value is greater
than the 99% percentile upper reference limit. For patients who die and for whom no cardiac markers were
obtained, the presence of new ST segment elevation and new chest pain would meet criteria for MI
Contrast-induced nephropathy 25% increase in serum creatinine concentration from the baseline value, or absolute increase of at least 0.5 mg/dL
(44.2 μmol/L), appearing within 48 h of administration of contrast media, and maintained for 2 to 5 days [94-96]
Cerebrovascular events Stroke is defined as a new focal neurological deficit of presumed vascular aetiology persisting >24 h combined
with a neurological imaging study that does not indicate a different aetiology. Transient ischaemic attack (TIA) is
any focal ischaemic neurological deficit of abrupt onset, which resolves completely within 24 h
Severe heart failure Early heart failure: any new onset cardiogenic shock or heart failure occurring after randomisation and during
the index admission with radiographic evidence of pulmonary oedema requiring intravenous diuretic therapy
Late heart failure: admission to hospital for treatment for documented New York Heart Association (NYHA)
class III or IV heart failure
Major bleeding Defined according to the TIMI criteria as fatal bleeding, any intracranial bleeding or clinically overt signs of
haemorrhage associated with a drop in haemoglobin (Hb) of≥ 50 g/L
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with a secondary analysis by treatment received. Patients
entering into the study but not completing the CMRI
will continue to be followed-up for MACE on an
intention-to-treat basis. Analysis of Variance (ANOVA)
will compare mean IS between groups. Each drug will be
compared to the control (that is, Adenosine vs. Control
and SNP vs. Control). Multivariable analysis using linear
regression will take into consideration possible confounders
such as sex, age and other co-morbidities. The major con-
founders of location of infarct (anterior/non-anterior) and
time from symptom onset to reperfusion will be addressed
by the stratified randomisation process. Other important
confounders, such as collateral blood flow to the infarct
territory determined by the Rentrop score [98], will be
controlled for in the statistical analysis. Secondary endpoint
analysis will employ time-to-event regression methods to
investigate potentially important predictors of MACE.
Sample size
Sample size has been based on previous observations
of significant correlation between the extent of CMR
measured MVO and IS (which on average is 20% of
LV mass as detected by CMR after P-PCI) [16]. Since
there are no available data regarding the incidence of
MVO with the study drugs assessed by CMR, and the
wealth of published data on IS following P-PCI, we
have chosen IS as the primary endpoint of the trial. IS
is a powerful predictor of ventricular function, adverse
LV remodeling and short-medium term clinical outcome
[13,15,16,99-111]. Furthermore, new infarct size of 4% ofLV mass has been shown to be associated with adverse
prognosis in patients with coronary artery disease under-
going revascularisation-related injury [112]. To detect a
reduction in IS from 20% to 15% of LV mass, assuming a
standard deviation of 10% [18,102,108,109,113-117], α of
0.05, two-tailed, 80% power and a drop-out rate of 20%
between P-PCI and CMR, 80 subjects per group (240 in
total) will be required.
Study organisation
The study is funded by the Medical Research Council
(MRC) and managed by the National Institute for Health
Research (NIHR) on behalf of the MRC-NIHR partner-
ship. The trial sponsor is the University Hospitals of
Leicester NHS Trust. Trial support will be provided by
the Leicester Clinical Trials Unit (UK Clinical Research
Collaboration (UKCRC) ID 43) who will be responsible
for database provision, data management and statistical
analysis. The study will be overseen by a Trial Steering
Committee (TSC), with an independent chair and two
additional independent members, which will have access
to the database after study completion and data-lock.
Efficacy and safety data (particularly unexpected adverse
events) will be scrutinised by an Independent Data and
Safety Monitoring Board (DSMB), which will report
back to the TSC. Clinical trials number NCT01747174
Clinicaltrials.gov.
Discussion
The REFLO-STEMI study has been designed to address
the weaknesses of previous trials, which have collectively
Nazir et al. Trials 2014, 15:371 Page 9 of 13
http://www.trialsjournal.com/content/15/1/371failed to demonstrate whether adjunctive pharmacother-
apy with adenosine and/or SNP can reduce measures of
myocardial injury (infarct size and MVO) and improve
clinical outcome, despite good basic evidence that they
have the potential to attenuate this process. The REFLO-
STEMI trial will be the first study to combine what are
considered appropriate efficacious drug dosages, delivered
optimally to the site of maximal benefit, with the use of
CMR to robustly measure reperfusion success, in a group
of patients treated with a contemporary reperfusion
strategy. The study will be powered accordingly to deliver
a definitive answer as to whether these agents can reduce
infarct size. Additional measures of myocardial perfusion
(angiographic and electrocardiographic) and early clinical
outcome data will provide further insight in to the
potential role of prophylactic adjunctive pharmacotherapy,
administered universally for STEMI patients or for those
selected by retrospective analyses to most benefit, augment-
ing the benefits of timely-delivered P-PCI. As the largest
and most scientifically robust trial to date, the REFLO-
STEMI study, alongside the existing combination of stud-
ies, will inform future STEMI Guideline committees.
Trial status
The REFLO-STEMI trial has successfully completed
recruitment of 247 patients. Follow-up and data collec-
tion are in progress and all investigators remain blinded
to outcome data.
Additional file
Additional file 1: Table S1. Main randomised controlled trials
investigating the role of adenosine and sodium nitroprusside (SNP) in
attenuating or preventing MVO in STEMI treated with P-PCI
[42,44,45,51-53,55-57,60,61,118,119]. Table S2. TIMI myocardial perfusion
grade (TMPG) [82]. Table S3. TIMI flow grade (TFG) classification [87].
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